GlaxoSmithKline: Key support at 1561p

GlaxoSmithKline and Sanofi, the two pharmaceutical giants, are discussing a 500 million pounds deal to supply the U.K. government with their potential coronavirus vaccine.

Charts (5)

GlaxoSmithKline and Sanofi, the two pharmaceutical giants, are discussing a 500 million pounds deal to supply the U.K. government with their potential coronavirus vaccine, reported Bloomberg citing people familiar with the matter. The UK is considering buying the vaccine if it shows convincing results in clinical trials scheduled to begin in September.  Sanofi, whose Pasteur Vaccines Division enjoys a solid reputation, particularly in the area of influenza, is currently working on two other projects.

 

From a chartist point of view, the stock price remains within a consolidation channel in place since April 2020. The daily Relative Strength Index (RSI, 14) is navigating around its neutrality area at 50%. The configuration is mixed. Prices need to stand above 1561p to maintain the short term bullish bias.  A push above 1749p would validate a new bullish signal and would open a path to see 1857p. Alternatively, a break below 1561p would call for a reversal down trend with 1490p and 1415p as targets.

Source: GAIN Capital, TradingView


More from Equities

Join our live webinars for the latest analysis and trading ideas. Register now

GAIN Capital UK Limited (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.